Oral vs intravenous tacrolimus-based induction therapy in renal transplantation.
Tojimbara
T
T
Department of Surgery III, Tokyo Women's Medical University, Japan.
Kimikawa
M
M
Nakajima
I
I
Sato
S
S
Nakamura
M
M
Ishida
H
H
Tanabe
K
K
Koyama
I
I
Utsumi
K
K
Sannomiya
A
A
Tsuji
K
K
Fuchinoue
S
S
Agishi
T
T
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D012263:Ribonucleosides / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D003404:Creatinine; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone